Naegis Pharmaceuticals Inc
Naegis Pharmaceuticals is an ophthalmology-focused biopharmaceutical company dedicated to developing new oral and topical therapies that target an under-exploited biological pathway. Their mission is to develop therapies for serious inflammatory eye diseases that are effective, safe, and do not require injections, thereby improving patient compliance and quality of life. They focus on addressing inflammation and damage in both front and back of the eye, with a pipeline centered on leukotriene pathways and novel molecules like N0651. The company is actively advancing its lead compound through clinical development and is open to partnerships beyond ophthalmology, targeting other inflammatory diseases such as lung disease, cardiovascular disease, and cancer.
Industries
Nr. of Employees
small (1-50)
Naegis Pharmaceuticals Inc
Suite 720 – 999 West Broadway, Vancouver, BC V5Z 1K5
Patents
Products
Lead dual-pathway leukotriene inhibitor (small molecule)
A clinical-stage small-molecule inhibitor designed to block both LTB4 and cysteinyl-leukotriene production, developed for topical and oral administration to treat inflammatory eye diseases.
Proprietary small-molecule compound library
A curated library of novel small molecules designed to inhibit leukotriene production, used for lead selection and optimization for ophthalmic and other inflammatory indications.
Lead dual-pathway leukotriene inhibitor (small molecule)
A clinical-stage small-molecule inhibitor designed to block both LTB4 and cysteinyl-leukotriene production, developed for topical and oral administration to treat inflammatory eye diseases.
Proprietary small-molecule compound library
A curated library of novel small molecules designed to inhibit leukotriene production, used for lead selection and optimization for ophthalmic and other inflammatory indications.
Services
Collaborative clinical development arrangements with ophthalmology clinical research organizations to advance lead compounds through clinical trials.
Business development and licensing discussions to apply proprietary small-molecule libraries to inflammatory diseases beyond ophthalmology.
Collaborative clinical development arrangements with ophthalmology clinical research organizations to advance lead compounds through clinical trials.
Business development and licensing discussions to apply proprietary small-molecule libraries to inflammatory diseases beyond ophthalmology.
Expertise Areas
- Leukotriene-targeted therapeutics
- Small-molecule medicinal chemistry
- Ophthalmic drug delivery (topical and oral)
- Preclinical ocular disease models
Key Technologies
- Small-molecule synthesis
- Dual-pathway leukotriene inhibition
- Topical ophthalmic formulation
- Oral formulation development
News & Updates
Naegis Pharmaceuticals announced the closing of a financing to support the advancement of a patented lead compound through to FDA IND approval for a Phase 2 clinical trial.
Naegis received notification from the US Patent Office that a patent for its lead compound, N0651, will issue on May 7th, 2024.
Naegis Pharmaceuticals announced the closing of a financing to support the advancement of a patented lead compound through to FDA IND approval for a Phase 2 clinical trial.
Naegis received notification from the US Patent Office that a patent for its lead compound, N0651, will issue on May 7th, 2024.